Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARK BARAKAT

Allopathic & Osteopathic Physicians Ophthalmology

NPI
1225214646
CMS profile
100649
Location
SCOTTSDALE, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$97,842.00

112 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 112 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARK BARAKAT

NPI 1225214646 · CMS profile ID 100649

Allopathic & Osteopathic Physicians / Ophthalmology

SCOTTSDALE, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 112 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1225214646?year=2019&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARK BARAKAT, NPI 1225214646, CMS profile ID 100649. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 112 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1225214646?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). MARK BARAKAT, NPI 1225214646, CMS profile ID 100649. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 112 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1225214646?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
MARK BARAKAT, NPI 1225214646, CMS profile ID 100649, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 112 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1225214646?year=2019&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

112 matching records · $97,842.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 112 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 112.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Genentech USA, Inc. $18.4308/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681324319 CMS
Bausch & Lomb, a division of Bausch Health US, LLC $121.0908/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684380681 CMS
Novartis Pharmaceuticals Corporation $8.7108/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658807943 CMS
Novartis Pharmaceuticals Corporation $26.7508/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658807931 CMS
Novartis Pharmaceuticals Corporation $476.7408/14/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658807882 CMS
Novartis Pharmaceuticals Corporation $1,940.9908/14/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658807887 CMS
Novartis Pharmaceuticals Corporation $8,200.0008/14/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658807891 CMS
Novartis Pharmaceuticals Corporation $104.7008/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658807899 CMS
Novartis Pharmaceuticals Corporation $50.0408/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658807906 CMS
Novartis Pharmaceuticals Corporation $324.2008/14/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658807913 CMS
Novartis Pharmaceuticals Corporation $12.0708/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658807845 CMS
Novartis Pharmaceuticals Corporation $186.4308/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658807849 CMS
Novartis Pharmaceuticals Corporation $1,064.3008/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658807853 CMS
Novartis Pharmaceuticals Corporation $8,200.0008/05/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658807861 CMS
Novartis Pharmaceuticals Corporation $77.7008/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658807867 CMS
Novartis Pharmaceuticals Corporation $43.0508/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658807873 CMS
Novartis Pharmaceuticals Corporation $625.3008/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658807879 CMS
Genentech USA, Inc. $7,260.0008/02/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681411837 CMS
Genentech USA, Inc. $3,347.9008/02/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681414687 CMS
Alcon Vision LLC $104.7107/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 665751807 CMS
Alcon Vision LLC $16.6507/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 665792057 CMS
Genentech, Inc. $14.5007/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681178041 CMS
Novartis Pharmaceuticals Corporation $37.4407/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659043427 CMS
Novartis Pharmaceuticals Corporation $32.1407/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658807919 CMS
Genentech USA, Inc. $148.3707/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681342777 CMS
Genentech, Inc. $167.0007/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681182443 CMS
Novartis Pharmaceuticals Corporation $29.5707/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658807935 CMS
Novartis Pharmaceuticals Corporation $45.5907/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659043321 CMS
Allergan Inc. $90.4307/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670081617 CMS
Novartis Pharmaceuticals Corporation $109.8507/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659043329 CMS
Novartis Pharmaceuticals Corporation $58.8706/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658807829 CMS
Genentech, Inc. $128.2506/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681169305 CMS
Allergan Inc. $9.9405/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670081613 CMS
Novartis Pharmaceuticals Corporation $265.0705/04/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659043305 CMS
Novartis Pharmaceuticals Corporation $1,750.0005/04/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659043309 CMS
Novartis Pharmaceuticals Corporation $11.5705/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659043313 CMS
Novartis Pharmaceuticals Corporation $130.0905/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659043315 CMS
Novartis Pharmaceuticals Corporation $20.0005/04/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659043319 CMS
Novartis Pharmaceuticals Corporation $212.0005/03/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658807953 CMS
Novartis Pharmaceuticals Corporation $125.0005/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659043303 CMS
Genentech USA, Inc. $27.1304/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681267731 CMS
Genentech, Inc. $8.6804/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681169473 CMS
Novartis Pharmaceuticals Corporation $35.8304/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659043324 CMS
Alimera Sciences, Inc. $93.9004/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691753241 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $490.0004/08/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709076461 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $490.0004/03/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709076459 CMS
Novartis Pharmaceuticals Corporation $96.2203/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659043295 CMS
Novartis Pharmaceuticals Corporation $26.5203/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658807838 CMS
Novartis Pharmaceuticals Corporation $32.9403/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659043299 CMS
EyePoint Pharmaceuticals US, Inc. $21.5703/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698072227 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $97,842.00 112
PY2020 $77,455.17 54
PY2021 $43,419.59 64
PY2022 $132,046.30 145
PY2023 $148,637.65 172
PY2024 $163,074.27 223
PY2025 $131,762.06 163

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $24,753.22 14
PY2025 Principal investigator $548,764.48 131
PY2024 Recipient $5,332.62 1
PY2024 Principal investigator $159,093.65 15
PY2023 Recipient $7,233.07 4
PY2023 Principal investigator $389,239.57 57
PY2022 Principal investigator $239,521.87 39
PY2021 Recipient $3,964.28 2
PY2021 Principal investigator $308,935.47 97
PY2020 Recipient $559.30 1
PY2020 Principal investigator $462,609.81 22
PY2019 Principal investigator $44,518.33 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

145 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Roche TCRC, Inc. $36,209.00 12/31/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211647292
Principal investigator 1 Ocular Therapeutix, Inc. $17,536.50 12/24/2025 Non-covered Recipient Entity
Research Network Arizona LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236524
Principal investigator 1 Ocular Therapeutix, Inc. $29,376.00 12/24/2025 Non-covered Recipient Entity
RETINA MACULA INSTITUTE OF ARIZONA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238231
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $22,518.00 12/22/2025 Non-covered Recipient Entity
Research Network Arizona LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220814613
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 12/17/2025 Non-covered Recipient Entity
Retina Macula Institute Of Arizona PLLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220763065
Principal investigator 1 Boehringer Ingelheim International GmbH $438.00 12/17/2025 Non-covered Recipient Entity
Retina Macula Institute Of Arizona PLLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220763067
Principal investigator 1 Boehringer Ingelheim International GmbH $104.40 12/17/2025 Non-covered Recipient Entity
Retina Macula Institute Of Arizona PLLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220763069
Principal investigator 1 Ocular Therapeutix, Inc. $2,700.00 12/15/2025 Non-covered Recipient Entity
Retina Macula Institute of Arizona- Scottsdale
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238237
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Retina Macula Institute Of Arizona PLLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220763063
Principal investigator 1 Ocular Therapeutix, Inc. $39,176.00 11/21/2025 Non-covered Recipient Entity
RETINA MACULA INSTITUTE OF ARIZONA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238229
Principal investigator 1 Ocular Therapeutix, Inc. $15,291.00 11/19/2025 Non-covered Recipient Entity
Research Network Arizona LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236520
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Retina Macula Institute Of Arizona PLLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220763061
Principal investigator 1 Notal Vision, Inc. $30.00 10/29/2025 Non-covered Recipient Entity
Retina Macula Institute of Arizona
NRICH No dispute reported 06/30/2026 1242751742
Principal investigator 1 Notal Vision, Inc. $60.00 10/29/2025 Non-covered Recipient Entity
Retina Macula Institute of Arizona
NRICH No dispute reported 06/30/2026 1242751744
Principal investigator 1 Notal Vision, Inc. $30.00 10/29/2025 Non-covered Recipient Entity
Retina Macula Institute of Arizona
NRICH No dispute reported 06/30/2026 1242751746
Principal investigator 1 Ocular Therapeutix, Inc. $10,012.50 10/29/2025 Non-covered Recipient Entity
Research Network Arizona LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236516
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 10/27/2025 Non-covered Recipient Entity
Retina Macula Institute Of Arizona PLLC
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220763043
Principal investigator 1 Ocular Therapeutix, Inc. $200.00 10/17/2025 Non-covered Recipient Entity
RETINA MACULA INSTITUTE OF ARIZONA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238233
Principal investigator 1 Ocular Therapeutix, Inc. $5,095.20 10/15/2025 Non-covered Recipient Entity
Retina Macula Institute of Arizona- Scottsdale
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238235
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,000.00 10/13/2025 Non-covered Recipient Entity
RETINA MACULA INSTITUTE OF ARIZONA
Real-World Patient Characteristics, Treatment Patterns, and Outcomes Among Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) Treated With Aflibercept 8 mg in the United States No dispute reported 06/30/2026 1184249943
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $18,352.00 10/10/2025 Non-covered Recipient Entity
Research Network Arizona LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220814609
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Retina Macula Institute Of Arizona PLLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220763059
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,649.00 10/01/2025 Non-covered Recipient Entity
Research Network Arizona LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220814611
Recipient F. Hoffmann-La Roche AG $753.57 10/01/2025 Covered Recipient Physician VA2 PhIII Yosemite No dispute reported 06/30/2026 1211537564
Principal investigator 1 Boehringer Ingelheim International GmbH $119.88 09/24/2025 Non-covered Recipient Entity
Retina Macula Institute Of Arizona PLLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220763053
Principal investigator 1 Boehringer Ingelheim International GmbH $292.00 09/24/2025 Non-covered Recipient Entity
Retina Macula Institute Of Arizona PLLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220763055
Principal investigator 1 Boehringer Ingelheim International GmbH $83.52 09/24/2025 Non-covered Recipient Entity
Retina Macula Institute Of Arizona PLLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220763057
Principal investigator 1 Ocular Therapeutix, Inc. $10,012.50 09/24/2025 Non-covered Recipient Entity
Research Network Arizona LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236512
Principal investigator 1 Ocular Therapeutix, Inc. $300.00 09/03/2025 Non-covered Recipient Entity
RETINA MACULA INSTITUTE OF ARIZONA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238225
Principal investigator 1 Ocular Therapeutix, Inc. $2,689.00 09/03/2025 Non-covered Recipient Entity
RETINA MACULA INSTITUTE OF ARIZONA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238227
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Retina Macula Institute Of Arizona PLLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220763047
Principal investigator 1 Boehringer Ingelheim International GmbH $43.00 09/01/2025 Non-covered Recipient Entity
Retina Macula Institute Of Arizona PLLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220763049
Principal investigator 1 Ocular Therapeutix, Inc. $12,410.10 08/27/2025 Non-covered Recipient Entity
Research Network Arizona LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236507
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $13,280.00 08/19/2025 Non-covered Recipient Entity
Research Network Arizona LLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220814607
Principal investigator 1 Ocular Therapeutix, Inc. $5,496.00 08/13/2025 Non-covered Recipient Entity
RETINA MACULA INSTITUTE OF ARIZONA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238221
Principal investigator 1 Ocular Therapeutix, Inc. $6,713.00 08/13/2025 Non-covered Recipient Entity
RETINA MACULA INSTITUTE OF ARIZONA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238223
Principal investigator 1 Astellas Pharma Global Development $7,793.00 08/11/2025 Non-covered Recipient Entity
Research Network Arizona LLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234185208
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $16,000.00 08/04/2025 Non-covered Recipient Entity
Research Network Arizona LLC
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220814615
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Retina Macula Institute Of Arizona PLLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220763045
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,062.00 07/31/2025 Non-covered Recipient Entity
RETINA MACULA INSTITUTE OF ARIZONA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184222688
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,572.00 07/31/2025 Non-covered Recipient Entity
RETINA MACULA INSTITUTE OF ARIZONA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184222690
Principal investigator 1 Astellas Pharma Global Development $1,432.00 07/28/2025 Non-covered Recipient Entity
Research Network Arizona LLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234185200
Principal investigator 1 Astellas Pharma Global Development $1,432.00 07/28/2025 Non-covered Recipient Entity
Research Network Arizona LLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234185202
Principal investigator 1 Astellas Pharma Global Development $1,432.00 07/28/2025 Non-covered Recipient Entity
Research Network Arizona LLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234185204
Principal investigator 1 Astellas Pharma Global Development $1,432.00 07/28/2025 Non-covered Recipient Entity
Research Network Arizona LLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234185206
Principal investigator 1 Astellas Pharma Global Development $1,432.00 07/28/2025 Non-covered Recipient Entity
Research Network Arizona LLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234185210
Principal investigator 1 Boehringer Ingelheim International GmbH $119.88 07/28/2025 Non-covered Recipient Entity
Retina Macula Institute Of Arizona PLLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220763051
Principal investigator 1 Ocular Therapeutix, Inc. $15,611.40 07/25/2025 Non-covered Recipient Entity
RETINA MACULA INSTITUTE OF ARIZONA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238219
Principal investigator 1 Ocular Therapeutix, Inc. $2,963.51 07/16/2025 Non-covered Recipient Entity
RETINA MACULA INSTITUTE OF ARIZONA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238217
Principal investigator 1 Alcon Research LLC $150.00 07/09/2025 Non-covered Recipient Entity
RESEARCH NETWORK ARIZONA LLC
Unity VCS Vit Ret Claims Study No dispute reported 06/30/2026 1220922600
Principal investigator 1 Alcon Research LLC $3,500.00 07/09/2025 Non-covered Recipient Entity
RESEARCH NETWORK ARIZONA LLC
Unity VCS Vit Ret Claims Study No dispute reported 06/30/2026 1220922602
Principal investigator 1 Alcon Research LLC $1,000.00 07/09/2025 Non-covered Recipient Entity
RESEARCH NETWORK ARIZONA LLC
Unity VCS Vit Ret Claims Study No dispute reported 06/30/2026 1220922604
Principal investigator 1 Ocular Therapeutix, Inc. $8,708.00 07/09/2025 Non-covered Recipient Entity
RETINA MACULA INSTITUTE OF ARIZONA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238211
Principal investigator 1 Ocular Therapeutix, Inc. $1,786.00 07/09/2025 Non-covered Recipient Entity
RETINA MACULA INSTITUTE OF ARIZONA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238213
Principal investigator 1 Ocular Therapeutix, Inc. $6,019.56 07/09/2025 Non-covered Recipient Entity
RETINA MACULA INSTITUTE OF ARIZONA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238215
Principal investigator 1 Ocular Therapeutix, Inc. $8,010.00 07/02/2025 Non-covered Recipient Entity
RETINA MACULA INSTITUTE OF ARIZONA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238207
Principal investigator 1 Ocular Therapeutix, Inc. $9,641.00 07/02/2025 Non-covered Recipient Entity
RETINA MACULA INSTITUTE OF ARIZONA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238209
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Retina Macula Institute Of Arizona PLLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220763033
Recipient Ocular Therapeutix, Inc. $10,013.51 06/30/2025 Covered Recipient Physician Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250229326
Principal investigator 1 Ocular Therapeutix, Inc. $1,100.00 06/23/2025 Non-covered Recipient Entity
RETINA MACULA INSTITUTE OF ARIZONA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238201
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $149.96 06/19/2025 Non-covered Recipient Entity
Retina Macula Institute Of Arizona PLLC
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220813589
Principal investigator 1 Ocular Therapeutix, Inc. $7,764.20 06/18/2025 Non-covered Recipient Entity
RETINA MACULA INSTITUTE OF ARIZONA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238197
Principal investigator 1 Ocular Therapeutix, Inc. $2,963.51 06/18/2025 Non-covered Recipient Entity
RETINA MACULA INSTITUTE OF ARIZONA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238199
Principal investigator 1 Ocular Therapeutix, Inc. $2,933.13 06/13/2025 Non-covered Recipient Entity
RETINA MACULA INSTITUTE OF ARIZONA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238189
Principal investigator 1 Ocular Therapeutix, Inc. $3,882.10 06/13/2025 Non-covered Recipient Entity
RETINA MACULA INSTITUTE OF ARIZONA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238191
Principal investigator 1 Ocular Therapeutix, Inc. $700.00 06/13/2025 Non-covered Recipient Entity
RETINA MACULA INSTITUTE OF ARIZONA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238193
Principal investigator 1 Ocular Therapeutix, Inc. $5,077.18 06/13/2025 Non-covered Recipient Entity
RETINA MACULA INSTITUTE OF ARIZONA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238195
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $16,075.00 06/02/2025 Non-covered Recipient Entity
Retina Macula Institute Of Arizona PLLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220813587
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Retina Macula Institute Of Arizona PLLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220763031
Principal investigator 1 Ocular Therapeutix, Inc. $10,012.50 05/23/2025 Non-covered Recipient Entity
RETINA MACULA INSTITUTE OF ARIZONA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238187
Principal investigator 1 Genentech, Inc. $4,992.00 05/22/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211647231
Principal investigator 1 Notal Vision, Inc. $30.00 05/21/2025 Non-covered Recipient Entity
Retina Macula Institute of Arizona
NRICH No dispute reported 06/30/2026 1242751740
Principal investigator 1 Ocular Therapeutix, Inc. $2,363.51 05/14/2025 Non-covered Recipient Entity
RETINA MACULA INSTITUTE OF ARIZONA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238181
Principal investigator 1 Ocular Therapeutix, Inc. $200.00 05/14/2025 Non-covered Recipient Entity
RETINA MACULA INSTITUTE OF ARIZONA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238183
Principal investigator 1 Ocular Therapeutix, Inc. $13,971.00 05/14/2025 Non-covered Recipient Entity
RETINA MACULA INSTITUTE OF ARIZONA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238185
Principal investigator 1 Ocular Therapeutix, Inc. $12,212.00 05/09/2025 Non-covered Recipient Entity
RETINA MACULA INSTITUTE OF ARIZONA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238179
Recipient Regeneron Pharmaceuticals, Inc. $1,828.00 05/07/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184115465
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
Retina Macula Institute Of Arizona PLLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220763029
Principal investigator 1 Notal Vision, Inc. $30.00 04/30/2025 Non-covered Recipient Entity
Retina Macula Institute of Arizona
NRICH No dispute reported 06/30/2026 1242751732
Principal investigator 1 Notal Vision, Inc. $30.00 04/30/2025 Non-covered Recipient Entity
Retina Macula Institute of Arizona
NRICH No dispute reported 06/30/2026 1242751734
Principal investigator 1 Notal Vision, Inc. $30.00 04/30/2025 Non-covered Recipient Entity
Retina Macula Institute of Arizona
NRICH No dispute reported 06/30/2026 1242751736
Principal investigator 1 Notal Vision, Inc. $30.00 04/30/2025 Non-covered Recipient Entity
Retina Macula Institute of Arizona
NRICH No dispute reported 06/30/2026 1242751738
Principal investigator 1 Ocular Therapeutix, Inc. $10,012.50 04/30/2025 Non-covered Recipient Entity
RETINA MACULA INSTITUTE OF ARIZONA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238177
Principal investigator 1 Roche TCRC, Inc. $3,084.00 04/25/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A STUDY TO INVESTIGATE RO7200394 AS NOVEL INTRAVITREAL TREATMENT FOR CENTRAL RETINAL VEIN OCCLUSION No dispute reported 06/30/2026 1211647288
Principal investigator 1 Ocular Therapeutix, Inc. $1,941.05 04/16/2025 Non-covered Recipient Entity
RETINA MACULA INSTITUTE OF ARIZONA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238175
Principal investigator 1 Ocular Therapeutix, Inc. $200.00 04/11/2025 Non-covered Recipient Entity
RETINA MACULA INSTITUTE OF ARIZONA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238161
Principal investigator 1 Ocular Therapeutix, Inc. $600.00 04/11/2025 Non-covered Recipient Entity
RETINA MACULA INSTITUTE OF ARIZONA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238163
Principal investigator 1 Ocular Therapeutix, Inc. $3,474.00 04/11/2025 Non-covered Recipient Entity
RETINA MACULA INSTITUTE OF ARIZONA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238165
Principal investigator 1 Ocular Therapeutix, Inc. $500.00 04/11/2025 Non-covered Recipient Entity
RETINA MACULA INSTITUTE OF ARIZONA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238167
Principal investigator 1 Ocular Therapeutix, Inc. $500.00 04/11/2025 Non-covered Recipient Entity
RETINA MACULA INSTITUTE OF ARIZONA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238169
Principal investigator 1 Ocular Therapeutix, Inc. $3,474.00 04/11/2025 Non-covered Recipient Entity
RETINA MACULA INSTITUTE OF ARIZONA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238171
Principal investigator 1 Ocular Therapeutix, Inc. $500.00 04/11/2025 Non-covered Recipient Entity
RETINA MACULA INSTITUTE OF ARIZONA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238173
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $239.30 04/03/2025 Non-covered Recipient Entity
Retina Macula Institute Of Arizona PLLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220813585
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
Retina Macula Institute Of Arizona PLLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220763027
Recipient F. Hoffmann-La Roche AG $6,397.75 03/31/2025 Covered Recipient Physician Human factors studies to assess the usability of the faricimab prefilled syringe by healthcare professionals No dispute reported 06/30/2026 1211537569
Principal investigator 1 Boehringer Ingelheim International GmbH $7.44 03/25/2025 Non-covered Recipient Entity
Retina Macula Institute Of Arizona PLLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220763023
Principal investigator 1 Boehringer Ingelheim International GmbH $69.96 03/25/2025 Non-covered Recipient Entity
Retina Macula Institute Of Arizona PLLC
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220763035
Principal investigator 1 Boehringer Ingelheim International GmbH $319.68 03/25/2025 Non-covered Recipient Entity
Retina Macula Institute Of Arizona PLLC
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220763037
Principal investigator 1 Boehringer Ingelheim International GmbH $328.50 03/25/2025 Non-covered Recipient Entity
Retina Macula Institute Of Arizona PLLC
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220763039
Principal investigator 1 Boehringer Ingelheim International GmbH $7.00 03/25/2025 Non-covered Recipient Entity
Retina Macula Institute Of Arizona PLLC
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220763041
Principal investigator 1 Ocular Therapeutix, Inc. $12,015.00 03/21/2025 Non-covered Recipient Entity
RETINA MACULA INSTITUTE OF ARIZONA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238205
Principal investigator 1 Notal Vision, Inc. $60.00 03/19/2025 Non-covered Recipient Entity
Retina Macula Institute of Arizona
NRICH No dispute reported 06/30/2026 1242751710
Principal investigator 1 Notal Vision, Inc. $60.00 03/19/2025 Non-covered Recipient Entity
Retina Macula Institute of Arizona
NRICH No dispute reported 06/30/2026 1242751712
Principal investigator 1 Notal Vision, Inc. $60.00 03/19/2025 Non-covered Recipient Entity
Retina Macula Institute of Arizona
NRICH No dispute reported 06/30/2026 1242751714
Principal investigator 1 Notal Vision, Inc. $60.00 03/19/2025 Non-covered Recipient Entity
Retina Macula Institute of Arizona
NRICH No dispute reported 06/30/2026 1242751716
Principal investigator 1 Notal Vision, Inc. $30.00 03/19/2025 Non-covered Recipient Entity
Retina Macula Institute of Arizona
NRICH No dispute reported 06/30/2026 1242751718
Principal investigator 1 Notal Vision, Inc. $30.00 03/19/2025 Non-covered Recipient Entity
Retina Macula Institute of Arizona
NRICH No dispute reported 06/30/2026 1242751720
Principal investigator 1 Notal Vision, Inc. $30.00 03/19/2025 Non-covered Recipient Entity
Retina Macula Institute of Arizona
NRICH No dispute reported 06/30/2026 1242751722
Principal investigator 1 Notal Vision, Inc. $30.00 03/19/2025 Non-covered Recipient Entity
Retina Macula Institute of Arizona
NRICH No dispute reported 06/30/2026 1242751724
Principal investigator 1 Notal Vision, Inc. $30.00 03/19/2025 Non-covered Recipient Entity
Retina Macula Institute of Arizona
NRICH No dispute reported 06/30/2026 1242751728
Principal investigator 1 Notal Vision, Inc. $30.00 03/19/2025 Non-covered Recipient Entity
Retina Macula Institute of Arizona
NRICH No dispute reported 06/30/2026 1242751730
Recipient Regeneron Pharmaceuticals, Inc. $3,831.92 03/12/2025 Covered Recipient Physician EYLEA CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184115463
Principal investigator 1 Ocular Therapeutix, Inc. $22,006.00 03/07/2025 Non-covered Recipient Entity
RETINA MACULA INSTITUTE OF ARIZONA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238203
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 03/01/2025 Non-covered Recipient Entity
Retina Macula Institute Of Arizona PLLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220763009
Recipient Regeneron Pharmaceuticals, Inc. $408.07 03/01/2025 Covered Recipient Physician A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184115451
Recipient Regeneron Pharmaceuticals, Inc. $150.00 03/01/2025 Covered Recipient Physician A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184115453
Recipient Regeneron Pharmaceuticals, Inc. $81.75 03/01/2025 Covered Recipient Physician A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184115455
Recipient Regeneron Pharmaceuticals, Inc. $21.80 03/01/2025 Covered Recipient Physician A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184115457
Recipient Regeneron Pharmaceuticals, Inc. $79.00 03/01/2025 Covered Recipient Physician A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184115459
Recipient Regeneron Pharmaceuticals, Inc. $21.80 03/01/2025 Covered Recipient Physician A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184115461
Recipient Regeneron Pharmaceuticals, Inc. $533.00 02/28/2025 Covered Recipient Physician A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184115447
Recipient Regeneron Pharmaceuticals, Inc. $184.25 02/28/2025 Covered Recipient Physician A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184115449
Principal investigator 1 Ocular Therapeutix, Inc. $11,775.00 02/26/2025 Non-covered Recipient Entity
RETINA MACULA INSTITUTE OF ARIZONA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238159
Principal investigator 1 Boehringer Ingelheim International GmbH $46.64 02/25/2025 Non-covered Recipient Entity
Retina Macula Institute Of Arizona PLLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220763011
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 02/25/2025 Non-covered Recipient Entity
Retina Macula Institute Of Arizona PLLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220763013
Principal investigator 1 Boehringer Ingelheim International GmbH $365.00 02/25/2025 Non-covered Recipient Entity
Retina Macula Institute Of Arizona PLLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220763015
Principal investigator 1 Boehringer Ingelheim International GmbH $85.84 02/25/2025 Non-covered Recipient Entity
Retina Macula Institute Of Arizona PLLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220763017
Principal investigator 1 Boehringer Ingelheim International GmbH $9.00 02/25/2025 Non-covered Recipient Entity
Retina Macula Institute Of Arizona PLLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220763019
Principal investigator 1 Boehringer Ingelheim International GmbH $1.83 02/25/2025 Non-covered Recipient Entity
Retina Macula Institute Of Arizona PLLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220763021
Principal investigator 1 Notal Vision, Inc. $60.00 02/18/2025 Non-covered Recipient Entity
Retina Macula Institute of Arizona
NRICH No dispute reported 06/30/2026 1242751688
Principal investigator 1 Notal Vision, Inc. $60.00 02/18/2025 Non-covered Recipient Entity
Retina Macula Institute of Arizona
NRICH No dispute reported 06/30/2026 1242751690
Principal investigator 1 Notal Vision, Inc. $60.00 02/18/2025 Non-covered Recipient Entity
Retina Macula Institute of Arizona
NRICH No dispute reported 06/30/2026 1242751692
Principal investigator 1 Notal Vision, Inc. $60.00 02/18/2025 Non-covered Recipient Entity
Retina Macula Institute of Arizona
NRICH No dispute reported 06/30/2026 1242751694
Principal investigator 1 Notal Vision, Inc. $30.00 02/18/2025 Non-covered Recipient Entity
Retina Macula Institute of Arizona
NRICH No dispute reported 06/30/2026 1242751696
Principal investigator 1 Notal Vision, Inc. $30.00 02/18/2025 Non-covered Recipient Entity
Retina Macula Institute of Arizona
NRICH No dispute reported 06/30/2026 1242751698
Principal investigator 1 Notal Vision, Inc. $30.00 02/18/2025 Non-covered Recipient Entity
Retina Macula Institute of Arizona
NRICH No dispute reported 06/30/2026 1242751700
Principal investigator 1 Notal Vision, Inc. $30.00 02/18/2025 Non-covered Recipient Entity
Retina Macula Institute of Arizona
NRICH No dispute reported 06/30/2026 1242751702
Principal investigator 1 Notal Vision, Inc. $30.00 02/18/2025 Non-covered Recipient Entity
Retina Macula Institute of Arizona
NRICH No dispute reported 06/30/2026 1242751706
Principal investigator 1 Notal Vision, Inc. $30.00 02/18/2025 Non-covered Recipient Entity
Retina Macula Institute of Arizona
NRICH No dispute reported 06/30/2026 1242751708
Principal investigator 1 Ocular Therapeutix, Inc. $26,507.00 02/05/2025 Non-covered Recipient Entity
RETINA MACULA INSTITUTE OF ARIZONA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238157
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
Retina Macula Institute Of Arizona PLLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220763007
Principal investigator 1 Genentech, Inc. $6,000.00 01/28/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211647236
Principal investigator 1 Roche TCRC, Inc. $6,127.00 01/21/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A STUDY TO INVESTIGATE RO7200394 AS NOVEL INTRAVITREAL TREATMENT FOR CENTRAL RETINAL VEIN OCCLUSION No dispute reported 06/30/2026 1211647284
Recipient Regeneron Pharmaceuticals, Inc. $448.80 01/14/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184115445
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 01/01/2025 Non-covered Recipient Entity
Retina Macula Institute Of Arizona PLLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220763025